Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NIM811 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| NIM811 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NIM811 | DRUG | BID in various doses (between 100 mg - 600 mg bid) + SOC (PEG IFN and RBV) |
| Placebo BID + SOC | DRUG | Placebo BID + SOC (PEG IFN and RBV) |
Inclusion criteria: Patients eligible for inclusion in this study have to fulfill all of the following criteria: * chronic hepatitis C genotype-1 * HCV-RNA should be ≥ 4 x 105 IU/mL at screening * Recipient of prior long acting interferon and ribavirin treatment for at least 12 weeks, with documen...
NIM811 is an investigational small molecule being studied for the treatment of chronic Hepatitis C genotype-1 relapse. It is intended for patients who have relapsed after prior therapy. The drug is administered in combination with standard of care for this condition.
NIM811 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with chronic Hepatitis C genotype-1 relapse.
NIM811 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness. The Phase 2 trial has been completed.
NIM811 has been studied in one completed Phase 2 clinical trial, identified as NCT00983060. This was a randomized, double-blind, placebo-controlled adaptive-design dose-finding study that evaluated the antiviral efficacy and safety of NIM811 combined with standard of care in relapsed Hepatitis C virus genotype-1 infected patients.
NIM811 is a small molecule that targets the Hepatitis C virus. It is designed to inhibit viral replication, thereby reducing the viral load in patients with chronic Hepatitis C genotype-1 relapse. The drug is intended to be used in combination with standard of care therapy.